


Characteristic & Category levels & Switch proportion & P-value\\
\hline
 & PCV7 vs NoVax & 80.0\% & \\
\cline{2-3}
 & PCV10 vs NoVax & 83.6\% & \\
\cline{2-3}
 & PCV13 vs NoVax & 71.2\% & \\
\cline{2-3}
\multirow[t]{-4}{*}{\raggedright\arraybackslash Type of comparison} & PCV13 vs PCV10 & 50.0\% & \multirow[t]{-4}{*}{\raggedleft\arraybackslash 0.049}\\
\cline{1-4}
 & Low & 78.6\% & \\
\cline{2-3}
 & Lower-middle & 81.8\% & \\
\cline{2-3}
\multirow[t]{-3}{*}{\raggedright\arraybackslash Income group} & Upper-middle & 73.6\% & \multirow[t]{-3}{*}{\raggedleft\arraybackslash 0.686}\\
\cline{1-4}
 & Excluded & 81.7\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Herd effects} & Included & 61.4\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.012}\\
\cline{1-4}
 & Excluded & 76.3\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Serotype replacement} & Included & 72.7\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.789}\\
\cline{1-4}
 & Healthcare/payer & 74.2\% & \\
\cline{2-3}
\multirow[t]{-2}{*}{\raggedright\arraybackslash Study perspective} & Societal & 78.1\% & \multirow[t]{-2}{*}{\raggedleft\arraybackslash 0.702}\\
\hline

